4-hydroxyphenylpyruvic acid has been researched along with Inflammation in 4 studies
4-hydroxyphenylpyruvic acid: RN given refers to parent cpd
4-hydroxyphenylpyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is substituted by a 4-hydroxyphenyl group.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parkins, A | 1 |
| Sandin, SI | 1 |
| Knittel, J | 1 |
| Franz, AH | 1 |
| Ren, J | 1 |
| de Alba, E | 1 |
| Pantouris, G | 1 |
| Scrima, R | 1 |
| Menga, M | 1 |
| Pacelli, C | 1 |
| Agriesti, F | 1 |
| Cela, O | 1 |
| Piccoli, C | 1 |
| Cotoia, A | 1 |
| De Gregorio, A | 1 |
| Gefter, JV | 1 |
| Cinnella, G | 1 |
| Capitanio, N | 1 |
| Kostevich, VA | 1 |
| Sokolov, AV | 1 |
| Grudinina, NA | 1 |
| Zakharova, ET | 1 |
| Samygina, VR | 1 |
| Vasilyev, VB | 1 |
| Cho, Y | 1 |
| Crichlow, GV | 1 |
| Vermeire, JJ | 1 |
| Leng, L | 1 |
| Du, X | 1 |
| Hodsdon, ME | 1 |
| Bucala, R | 1 |
| Cappello, M | 1 |
| Gross, M | 1 |
| Gaeta, F | 1 |
| Johnson, K | 1 |
| Lolis, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma[NCT03782415] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-29 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for 4-hydroxyphenylpyruvic acid and Inflammation
| Article | Year |
|---|---|
Underrepresented Impurities in 4-Hydroxyphenylpyruvate Affect the Catalytic Activity of Multiple Enzymes.
Topics: Catalytic Domain; Humans; Inflammation; Neoplasms; Phenylpyruvic Acids | 2023 |
Para-hydroxyphenylpyruvate inhibits the pro-inflammatory stimulation of macrophage preventing LPS-mediated nitro-oxidative unbalance and immunometabolic shift.
Topics: Animals; Anti-Inflammatory Agents; Cell Respiration; Fibroblasts; Humans; Hypoxia-Inducible Factor 1 | 2017 |
Interaction of macrophage migration inhibitory factor with ceruloplasmin: role of labile copper ions.
Topics: Animals; Ceruloplasmin; Copper; Galactosamine; Inflammation; Intramolecular Oxidoreductases; Ions; L | 2015 |
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.
Topics: Allosteric Site; Binding Sites; Catalysis; Chemotaxis; Crystallography, X-Ray; Cytokines; Humans; In | 2010 |
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.
Topics: Allosteric Site; Binding Sites; Catalysis; Chemotaxis; Crystallography, X-Ray; Cytokines; Humans; In | 2010 |
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.
Topics: Allosteric Site; Binding Sites; Catalysis; Chemotaxis; Crystallography, X-Ray; Cytokines; Humans; In | 2010 |
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.
Topics: Allosteric Site; Binding Sites; Catalysis; Chemotaxis; Crystallography, X-Ray; Cytokines; Humans; In | 2010 |